Grifols S.A. (GRFS)'s Financial Results Comparing With GW Pharmaceuticals plc (NASDAQ:GWPH)
This is a contrast between Grifols S.A. (NASDAQ:GRFS) and GW Pharmaceuticals plc (NASDAQ:GWPH) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Drug Manufacturers - Major and they also compete with each other.Valuation & Earnings
Table 1 highlights Grifols S.A. and GW Pharmaceuticals plc's top-line revenue, earnings per share (EPS) and valuation.Profitability
Table 2 provides us Grifols S.A. and GW Pharmaceuticals plc's return on equity, return on assets and net margins.Analyst Ratings
The table given features the ratings and recommendations for Grifols S.A. and GW Pharmaceuticals plc.
Grifols S.A. has a 0.96% upside potential and a consensus target price of $21. Competitively the average target price of GW Pharmaceuticals plc is $212.5, which is potential 79.92% upside. The data provided earlier shows that GW Pharmaceuticals plc appears more favorable than Grifols S.A., based on analyst view.Insider & Institutional Ownership
Grifols S.A. and GW Pharmaceuticals plc has shares owned by institutional investors as follows: 60.84% and 80.9%. Comparatively, 0.62% are GW Pharmaceuticals plc's share owned by insiders.Performance
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Grifols S.A. has weaker performance than GW Pharmaceuticals plcSummary
GW Pharmaceuticals plc beats on 6 of the 11 factors Grifols S.A.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. It is also developing Sativex in Phase II trials in neuropathic pain. In addition, the companyÂ's product pipeline includes Epidiolex, which is in Phase III clinical development for the treatment of dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis complex, and infantile spasms, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, adult epilepsy, and schizophrenia. It primarily operates Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
More News in Business
Abstract: The primary objective of the ' Global Basmati Rice Market 2020-2029 ' research is to describe the complete characteristics of the industry, size of the various segments and the geographies as well as
A Goldman Sachs banker has been charged with insider trading in a scheme that allegedly generated $2.6m in illegal profits as he tipped off a trader about multibillion-dollar deals involving bank clients like Syngenta. Bryan Cohen,
A Chick-fil-A restaurant that opened in the United Kingdom amid protests against the company's opposition to same-sex marriage will close in the next six months. >> Read more trending news Officials at The Oracle, a
Stock Markets 13 minutes ago (Oct 19, 2019 23:25) © Reuters. Goldman Sachs investment banker charged in insider trading scheme By David Shepardson (Reuters) - A Goldman Sachs Group Inc (N:) investment banker was released
FAYETTEVILLE, Ark. (KNWA) - George's Prepared Foods is recalling approximately 6,444 pounds of ready-to-eat pork and turkey sausage patty products that may be contaminated with salmonella, the U.S. Department of Agriculture announced on Friday. Affected products
New Market Research on Global LED Chips Market released by Market Research Store. The study comprised of 100+ market data Graphs & Figures, Pie Chat, and Tables. The report has a detailed